Articles related to DRUG EFFICACY

A randomized noninferiority trial found that oral fosfomycin matched continued intravenous therapy in stabilized patients with ESBL complicated UTIs after 3 to 7 days of initial IV treatment.

A systematic review of 43 randomized controlled trials found high-certainty evidence that multiple CGRP-targeted therapies reduced monthly migraine headache days by approximately 2 days versus placebo in adults with chronic migraine.

The LRRK2 inhibitor BIIB122 failed to slow disease progression versus placebo in 648 early-stage idiopathic Parkinson’s patients in the Phase 2b LUMA trial, leading Biogen and Denali to discontinue joint development.

Neoadjuvant apalutamide plus abiraterone and ADT before radical prostatectomy was associated with improved 12-month potency recovery and lower positive surgical margin rates compared with surgery alone in a small phase 2 trial of men with high-risk localized prostate cancer.

Two Lilly-sponsored placebo-controlled trials found that adults who transitioned from high-dose injectable GLP-1 therapy to either oral tirzepatide (Foundayo) or a reduced 5 mg tirzepatide maintenance dose preserved most of their prior weight loss over one year, compared to substantial regain in placebo arms.

Most newly diagnosed focal epilepsy patients required more than a year and more than one antiseizure medication to reach seizure freedom in a multicenter cohort.